Moody's Upgrades Teva to Investment Grade, Marking Milestone in Pivot to Growth Strategy
核心洞察
Moody's Ratings upgraded Teva's corporate credit rating to Baa3 from Ba1, achieving investment-grade status with a stable outlook on August 11, 2026.
The upgrade reflects Teva's successful growth strategy execution, including innovative product performance, pipeline expansion, and continued debt reduction supported by earnings growth.
This milestone follows Fitch Ratings' upgrade in May 2026, further strengthening Teva's credit standing and supporting eligibility for leading fixed-income indices.
Teva Pharmaceutical Industries Ltd. announced on August 11, 2026, that Moody's Ratings has upgraded the company's corporate credit rating to Baa3 from Ba1, elevating Teva to investment-grade status with a stable outlook. The upgrade, announced from Tel Aviv, Israel, represents a significant validation of the company's multi-year transformation under its "Pivot to Growth" strategy.
Moody's cited several factors underpinning the rating action, including the ongoing success of Teva's growth strategy, the performance of its key innovative products, an expanded pipeline, and continued debt reduction supported by earnings growth. The agency also highlighted Teva's revenue diversity, improving operating margins, solid free cash flow, and ample cash on hand. Moody's further expressed its expectation that Teva will continue to reduce debt over the next 12 to 18 months.
"Moody's upgrade to investment grade marks a major milestone in Teva's transformation journey and further validates the progress we're making through our Pivot to Growth strategy," said Eli Kalif, Teva's Chief Financial Officer. "This recognition, together with Fitch's upgrade in May, reflects years of disciplined execution, continued debt reduction and a stronger financial profile. It enhances Teva's financial flexibility and access to a broader base of investors as we continue to invest in growth, advance innovation for patients and create long-term value for our stakeholders."
The Moody's upgrade follows a similar action by Fitch Ratings in May 2026, further strengthening Teva's credit standing across major rating agencies. The dual investment-grade ratings support Teva's eligibility for inclusion in leading fixed-income indices, potentially broadening the company's investor base.
Teva, with over 120 years of history, is transforming into a leading innovative biopharmaceutical company supported by a world-class generics business. The company focuses on neuroscience and immunology innovation while also providing complex generic medicines, biosimilars, and pharmacy brands worldwide. The Pivot to Growth strategy has been central to Teva's efforts to expand its innovative and biosimilar medicines pipeline, sustain its generics portfolio, and execute organizational transformation aimed at achieving cost savings and improved financial performance.